Fact CheckerSign in

NCT07089914Completed

Health Surveillance at University of Applied Science Hamburg (HAW)

Health Surveillance at University of Applied Science Hamburg (HAW) in the Year 2025 to Assess Employees Health and Wellbeing

Source: ClinicalTrials.gov · Last updated 25 Sept 2026

Brief summary (registry, in English)

The aim of Health Surveillance 2025 is to analyze and describe the state of health of employees at University of Applied Science Hamburg, key influencing factors and individual resources.

Status (registry)
Completed
Study type
Observational
Enrollment
679 (actual)
First submitted
22 Jul 2025
Start date
14 May 2025
Primary completion date
30 Jul 2025
Lead sponsor
Jacobs University Bremen gGmbH
NCT number
NCT07089914

What you commit to

  • Study type: Observational
  • Participants enrolled: 679
  • From 14 May 2025 to the primary completion date, 30 Jul 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Illiteracy
  • Massively limited cognitive abilities i.e. linguistic components of the digital offerings must be able to be used, and questionnaires completed, or interviews participated in)

Who the study is looking for

  • German language skills
  • Reading and writing skills
  • Internet access
  • Employee status
  • Consent to participate in the study

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hamburg University of Applied Sciences/Hochschule für Angewandte Wissenschaften Hamburg (HAW Hamburg)
Coordinator of this site? Confirm its status
HamburgGermanyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.